Atara Biotherapeutics Inc. (ATRA) Rating Increased to Hold at Zacks Investment Research
Atara Biotherapeutics Inc. (NASDAQ:ATRA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Monday.
According to Zacks, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. “
A number of other equities research analysts also recently issued reports on the stock. Citigroup Inc. boosted their price target on shares of Atara Biotherapeutics from $8.00 to $10.00 and gave the company a “sell” rating in a research note on Friday, August 19th. Jefferies Group reaffirmed a “buy” rating and set a $25.00 target price on shares of Atara Biotherapeutics in a research note on Sunday, July 10th. Goldman Sachs Group Inc. downgraded shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating and cut their target price for the stock from $23.00 to $16.00 in a research note on Thursday, September 15th. Finally, JMP Securities reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research note on Saturday, July 9th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $26.14.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/10/atara-biotherapeutics-inc-atra-rating-increased-to-hold-at-zacks-investment-research.html
Shares of Atara Biotherapeutics (NASDAQ:ATRA) traded up 6.81% during midday trading on Monday, reaching $18.50. 125,724 shares of the company’s stock traded hands. The stock’s market capitalization is $533.00 million. Atara Biotherapeutics has a 1-year low of $13.31 and a 1-year high of $40.80. The firm’s 50-day moving average price is $20.16 and its 200 day moving average price is $20.32.
Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Monday, August 8th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.05. On average, equities analysts predict that Atara Biotherapeutics will post ($2.85) earnings per share for the current fiscal year.
In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 28th. The shares were sold at an average price of $20.87, for a total transaction of $250,440.00. Following the completion of the transaction, the chief executive officer now owns 406,578 shares in the company, valued at approximately $8,485,282.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Isaac E. Ciechanover sold 7,200 shares of the business’s stock in a transaction that occurred on Friday, September 16th. The stock was sold at an average price of $19.36, for a total transaction of $139,392.00. Following the transaction, the chief executive officer now owns 229,136 shares of the company’s stock, valued at approximately $4,436,072.96. The disclosure for this sale can be found here. Company insiders own 16.10% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of ATRA. Barclays PLC boosted its position in shares of Atara Biotherapeutics by 2,266.0% in the second quarter. Barclays PLC now owns 4,803 shares of the company’s stock valued at $108,000 after buying an additional 4,600 shares during the last quarter. BlackRock Inc. boosted its position in shares of Atara Biotherapeutics by 464.3% in the second quarter. BlackRock Inc. now owns 6,100 shares of the company’s stock valued at $137,000 after buying an additional 5,019 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Atara Biotherapeutics by 6,736.5% in the second quarter. PNC Financial Services Group Inc. now owns 6,563 shares of the company’s stock valued at $148,000 after buying an additional 6,467 shares during the last quarter. Franklin Street Advisors Inc. NC bought a new position in shares of Atara Biotherapeutics during the third quarter valued at about $214,000. Finally, BlackRock Advisors LLC boosted its position in shares of Atara Biotherapeutics by 30.2% in the second quarter. BlackRock Advisors LLC now owns 10,186 shares of the company’s stock valued at $229,000 after buying an additional 2,361 shares during the last quarter. Institutional investors own 75.50% of the company’s stock.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.